Table 3.
Comparative assessment of budesonide‐MMX and mesalamine in active, mild‐to‐moderate ulcerative colitis
| A. Induction of clinical and endoscopic remission | |||
|---|---|---|---|
| SUCRA value (%) | Probability best (%) | Mean rank | |
| Budesonide‐MMX | 75.3 | 45.5 | 1.7 |
| Mesalamine >2.4 g/day | 84.4 | 54.1 | 1.5 |
| Mesalamine 1.6–2.4 g/day | 40.3 | 0.4 | 2.8 |
| Placebo | 0.0 | 0.0 | 4.0 |
| B. Serious adverse events | |||
|---|---|---|---|
| SUCRA value (%) | Probability best (%) | Mean rank | |
| Budesonide‐MMX | 20.5 | 7.6 | 3.4 |
| Mesalamine >2.4 g/day | 79.2 | 61.8 | 1.6 |
| Mesalamine 1.6–2.4 g/day | 51.9 | 13.4 | 2.4 |
| Placebo | 48.4 | 17.2 | 2.5 |
| C. Treatment discontinuations or withdrawals from the study due to adverse events | |||
|---|---|---|---|
| SUCRA value (%) | Probability best (%) | Mean rank | |
| Budesonide‐MMX | 23.0 | 0.3 | 3.3 |
| Mesalamine >2.4 g/day | 96.7 | 90.3 | 1.1 |
| Mesalamine 1.6–2.4 g/day | 68.9 | 9.4 | 1.9 |
| Placebo | 11.5 | 0.0 | 3.7 |
Herein we present: (i) the SUCRA values providing the hierarchy of the competing treatments, (ii) the estimated probabilities of each treatment being the best, and (iii) the mean rank of each treatment using 10,000 draws.
SUCRA, surface under the cumulative ranking area